Effet d'Atorvastatine à dose fixe/Fénofibrate comparé à l'Atorvastatine sur le profil lipidique chez les patients atteints de diabète de type 2 et de dyslipidémie

This clinical trial aims to evaluate the effectiveness and safety of a fixed-dose combination of Atorvastatin and Fenofibrate compared to Atorvastatin alone in managing the lipid profile of patients with type 2 diabetes and dyslipidemia. Dyslipidemia is a condition characterized by high levels of triglycerides and LDL (Low-density lipoprotein) cholesterol. This study targets patients who require pharmacological treatment for lipid control, aiming to improve their lipid profile numbers and overall health. The outcomes of this study could potentially enhance the care and treatment of patients with type 2 diabetes and dyslipidemia. Participants in this study will receive either the fixed-dose combination of Atorvastatin and Fenofibrate or Atorvastatin alone. The study will measure the change in lipid profile figures, including LDL cholesterol, Lp(a), and triglycerides, at 2 and 4 months compared to the baseline measurements. Additionally, the study will assess the proportion of subjects who achieve a reduction in LDL cholesterol by more than 30% from their baseline value and those who achieve triglyceride levels below 150 mg/dL at the end of treatment. The study also aims to evaluate the effect on anthropometric, biochemical, and clinical indicators, as well as any adverse reactions that may occur.